CD8A and cancer: Then, they migrate to the draining lymph node and simultaneously cross‐present the protein antigens for priming of naive CD8+ T cells.[14] The cross‐presentation is tightly regulated and disabled with tumor progression to certain extent.[16] In contrast, mRNA vaccines, which naturally simulate MHC I type presentation, have superiority when applicated in cancer therapy.